Global menu

Our global pages


Eversheds comment: Pharmaceuticals’ concerns telling of wider UK industry/regulator tension

  • United Kingdom


    In response to calls from the pharmaceutical industry that the number of medicines being blocked from the UK market by the National Institute for Health and Care Excellence (NICE) is too high, Simon Crossley, partner and head of life sciences at global law firm, Eversheds, comments: 

    “With UK government austerity measures showing no signs of fading, there is an obvious tension between the pharmaceutical industry and NICE. While the industry understandably wants to access markets for new products, NICE effectively creates a further hurdle once clinical trials have been successful, to ensure that new medicines, made available through public funds, are assessed to ensure treatments are cost effective. NICE decisions are being regularly challenged by the industry in private and it’s telling that a group of companies have now gone public with their concerns, forcing NICE to justify its stance.”


    This information is for guidance purposes only and should not be regarded as a substitute for taking legal advice. Please refer to the full terms and conditions on our website.

    < Go back

    Print Friendly and PDF
    Register to receive regular updates via email.